Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
9.085 USD | +0.61% | +13.99% | -11.88% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 75.86M | Sales 2025 * | 89.25M | Capitalization | 259M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -29M | EV / Sales 2024 * | 3.72 x |
Net Debt 2024 * | 22.63M | Net Debt 2025 * | 43.9M | EV / Sales 2025 * | 3.4 x |
P/E ratio 2024 * |
-7.76
x | P/E ratio 2025 * |
-9.02
x | Employees | 171 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.19% |
Latest transcript on NeuroPace, Inc.
1 day | +6.11% | ||
1 week | -28.33% | ||
Current month | -30.48% | ||
1 month | -32.61% | ||
3 months | -43.84% | ||
6 months | +3.79% | ||
Current year | -12.42% |
Managers | Title | Age | Since |
---|---|---|---|
Joel Becker
CEO | Chief Executive Officer | 56 | 23-07-09 |
Rebecca Kuhn
FOU | Founder | 63 | 97-11-18 |
Frank Fischer
FOU | Founder | 82 | 97-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lisa Andrade
BRD | Director/Board Member | 52 | 21-10-31 |
Joseph Lacob
BRD | Director/Board Member | 68 | 97-11-18 |
Frank Fischer
FOU | Founder | 82 | 97-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 9.085 | +0.61% | 5 445 |
24-05-15 | 9.03 | +6.11% | 152,173 |
24-05-14 | 8.51 | -0.12% | 44,642 |
24-05-13 | 8.52 | +0.24% | 250,455 |
24-05-10 | 8.5 | +6.65% | 336,451 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.42% | 259M | |
+12.85% | 229B | |
+13.88% | 195B | |
+18.39% | 142B | |
+28.78% | 109B | |
+1.67% | 64.85B | |
+18.24% | 54.33B | |
+7.04% | 52.09B | |
+10.83% | 45.15B | |
+5.94% | 37.39B |
- Stock Market
- Equities
- NPCE Stock